<![CDATA[CagriSema Demonstrates Superior Hemoglobin and Weight Loss Results in Type 2 Diabetes]]>
Novo Nordisk announced headline results from the REIMAGINE 2 (NCT06065540) phase 3 trial, revealing that its experimental therapy, CagriSema, achieved statistically significant superiority in both blood glucose control and weight reduction for adults with …